Evidence map›Paper›PMID 36073562›Full record

ReviewAsian journal of andrology

Circadian rhythm in prostate cancer: time to take notice of the clock.

Wei-Zhen Zhu, Qi-Ying He, De-Chao Feng, Qiang Wei, Lu Yang

Open access · goldAbstract readReview
In one paragraph

Review in Asian journal of andrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Circadian rhythm disruption and endocrine-related tumors.World journal of clinical oncology · 2024
    Review
  6. Natural Compounds for Preventing Age-Related Diseases and Cancers.International journal of molecular sciences · 2024
    Review
  7. Review
  8. Review
  9. Biological clock regulation by theFrontiers in cell and developmental biology · 2024
    Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Wei-Zhen ZhuDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Qi-Ying HeDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
De-Chao FengDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Qiang WeiDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Lu YangDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The circadian clock is an evolutionary molecular product that is associated with better adaptation to changes in the external environment. Disruption of the circadian rhythm plays a critical role in tumorigenesis of many kinds of cancers, including prostate cancer (PCa). Integrating circadian rhythm into PCa research not only brings a closer understanding of the mechanisms of PCa but also provides new and effective options for the precise treatment of patients with PCa. This review begins with patterns of the circadian clock, highlights the role of the disruption of circadian rhythms in PCa at the epidemiological and molecular levels, and discusses possible new approaches to PCa therapy that target the circadian clock.

Indexed as

Circadian ClocksCircadian RhythmProstatic NeoplasmsCarcinogenesisHumansMalechronotherapycircadian clockcircadian rhythmprostate cancer

Identifiers

PMID36073562
PMCPMC10069698
OpenAlexW4294754138

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.